Rituximab as a single agent for successful treatment of granulomatous and lymphocytic interstitial lung disease in a pediatric patient with common variable immunodeficiency

Abstract

Granulomatous and lymphocytic interstitial lung disease (GLILD) occurs in 10% to 20 % of adult patients with common variable immunodeficiency (CVID).1 The frequency of GLILD in pediatric CVID is not well established, but various forms of interstitial lung disease were reported in 15% of children.2 There is a lack of robust scientific evidence on how to treat and when to start treatment of GLILD, but most regiments aim at T and B lymphocytes. Experience with the effectiveness of systemic steroids has been diverse.